The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with nicotinamide Authors: Lotte Nijhuis, Rianne C Scholman, Arief Lalmohamed, Sebastiaan J Vastert, Jorg van Loosdregt Published: 2026 ABSTRACT AbstractBackgroundJuvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children and is characterized by chronic joint inflammation driven by immune dysregulation. A disturbed regulatory T (Treg) cell-effector T cell axis has been demonstrated in these patients which contributes to a dysregulated immune tolerance in JIA. Therefore, strategies to enhance Treg numbers and suppressive capacity to restore immune homeostasis represent a promising therapeutic approach. Nicotinamide (NAM), a form of vitamin B₃ and precursor of nicotinamide adenine dinucleotide (NAD⁺), has emerged as an immunomodulator capable of promoting Treg cell function.MethodsHere, we investigate the effects of NAM on Treg percentages and suppressive capacity in mononuclear cells derived from peripheral blood (PBMCs) and synovial fluid of JIA patients (SFMCs). In an exploratory pilot phase II clinical study, NAM concentrations were measured in paired blood plasma and SF from 6 JIA patients after oral administration of daily 1.8 g/m2 for three days.ResultsNAM treatment significantly increased the proportion of FOXP3-expressing CD4+ T cells in both PBMCs and SFMCs and Treg suppressive capacity in PBMCs from healthy controls in vitro. Comparable NAM concentrations were detected in plasma and SF following oral administration, demonstrating its ability to penetrate the inflamed joint environment.ConclusionGiven its established safety in both adults and children, NAM represents a promising future candidate for adjunctive therapy in JIA by restoring the balance between regulatory and effector T cells. Further clinical and mechanistic studies are warranted to define optimal dosing regimens and its place in the long-term treatment strategy of JIA.Trial registrationAssessing penetration of high dose nicotinamide (Vitamin B3) in synovial fluid. EudraCT Number: 2018-002245-11, start date Jan 16th, 2019.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13075-026-03846-2.Keywords: NAM, Nicotinamide, Treg, JIA, Auto-immune disease Background Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children and comprises a heterogeneous group of disorders, each characterized by distinct disease pathogenesis [1–3]. In the non-systemic subtypes of JIA, particularly oligoarticular JIA and polyarticular JIA, CD4+ T cells play a central role in disease pathogenesis [4]. Within the CD4+ T cell compartment, regulatory T (Treg) cells are essential for maintaining immune homeostasis and preventing excessive inflammation by their capacity to suppress other immune cells [5, 6]. Treg cells are typically identified in literature as CD4+CD25highCD127low T cells and are characterized by the expression of the transcription factor Forkhead BoxP3 (FOXP3), which is crucial for their differentiation and suppressive function [7–12]. This critical role for FOXP3 is exemplified in immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, where mutations in the FOXP3 gene lead to a severe auto-immune disorder due to Treg deficiency [13, 14]. Impaired Treg numbers and/or function have been implicated in the pathogenesis of JIA [3, 15–19]. Consequently, strategies aimed at restoring or enhancing Treg function have emerged as promising investigational approaches [4, 20, 21]. However, available research data is not consistent and various studies reported that Treg numbers in synovial fluid (SF) of JIA patients are equal or even increased rather than reduced compared to peripheral blood [22]. Furthermore, available data indicates that effector T cells isolated from the inflamed joint can become resistant to Treg-mediated suppression, a process at least partly driven by hyperactivation of the PKB/c-akt pathway in response to pro-inflammatory cytokines [23]. This suggests that the inflammatory environment within the joint alters the effector T cells making them less responsive to their regulatory signals [23–26]. Collectively, these studies demonstrate that JIA is not only characterized by numerical alterations in Treg populations but also by dysfunction of the regulatory-effector T cell balance. Therefore, therapeutic strategies aimed at enhancing Treg suppressive capacity- either by expanding Treg numbers or restoring effector T cell responses- could offer a promising future approach to re-establish immune homeostasis in JIA [21]. However, current available treatments, including disease-modifying antirheumatic drugs (DMARD’s) and biologicals, predominantly target effector T cells activity, with limited effects on Treg modulation [27]. A promising therapeutic approach to improve Treg-effector T cell balance involves nicotinamide (NAM), a form of vitamin B3 and precursor of nicotinamide adenine dinucleotide adenine (NAD+). NAM has been recognized for years for its immunomodulatory and auto-inflammatory features both in vivo and in vitro [28–32]. Recent findings show that NAM can attenuate CD4+ T cell activation and effector functions [33]. In addition to these effects on CD4+ T cell effector function, NAM has also been shown to promote immune homeostasis by increasing the proportion of FOXP3-expressing CD4+ T cells in vitro [9, 34]. While the precise mechanism by which NAM exerts its immunomodulatory effects remains a topic of ongoing debate, its ability to simultaneously suppress effector T cell responses and support Treg suppressive function, together with available data demonstrating a favorable safety profile, makes it an attractive candidate for maintenance treatment in autoimmune diseases such as JIA. In this study we demonstrate that NAM increases the proportion of FOXP3-expressing CD4+T cells in vitro. In addition, NAM pre-treatment reduces the proliferation of CD4+ and CD8+ T cells in peripheral blood mononuclear cells (PBMCs) from healthy donors as well as synovial fluid mononuclear cells (SFMCs) from JIA patients. To further explore the feasibility of NAM treatment in JIA, NAM was orally administered in a dosage of 1.8 g/m2/day to 6 patients with JIA. The concentrations of NAM in SF were comparable to those observed in the peripheral blood after NAM administration, supporting the potential to exert its immunomodulatory effects both systemically and in the inflamed joint. Collectively these findings provide supporting evidence to further investigate oral NAM administration as a safe, adjunctive immunoregulatory treatment for JIA. Methods Cell culture Human PBMCs were obtained from blood from healthy adult volunteers (aged 25–65 years; both male and female) and isolated using Ficoll-paque plus density gradient media. SFMCs and PBMCs were obtained from 5 children with the diagnosis of JIA who were included in the Pharmachild registry (METC protocol 11–499) and had active disease at the time of sampling and an indication for intra-articular corticosteroid injection. Cells were cultured in RPMI 1640 medium (Thermo Fisher, Hampton, NH, USA) supplemented with Il-2 (300IU/ml) [36, 37] and 10% heat-inactivated human AB serum (Merck Life Science, Darmstadt, Germany) in the presence of 1% glutamine (Merck Life Science) and 1% penicillin-streptomycin (Merck Life Science). Cells were stimulated with coated aCD3 1,5ug/ml (OKT3 eBioscience™, San Diego, USA). Anti-CD28 co-stimulation was added as cells were co-cultured with APCs, which provide sufficient co-stimulatory signals within the PBMC/SFMC culture conditions. Nicotinamide (Sigma-Aldrich, Saint-Louis, USA) was dissolved in culture medium and added in the treatment conditions in different concentrations ranging from 1mM to 9mM. All cells were cultured at 37 °C in 5% CO2. Medium was refreshed at day 2 of incubation. Flow cytometry Cells were washed in FACS buffer (PBS with 2% FCS and 0.1% NaN3) and stained with antibodies (Supplementary table S1). For intracellular FOXP3 staining, cells were fixed and permeabilized with fixation/permeabilization concentrate diluted in a 1:4 ratio with fixation/permeabilization diluent specific for transcription factors and nuclear proteins (eBioscience™). Measurements were performed using the BD FACSCanto™ II flow cytometer, and FlowJo v10 was used for data analysis. Both PBMCs and SFMCs were gated using an identical strategy, selecting lymphocytes and subsequently single cells and gated on CD3⁺CD4⁺ populations (Gating strategy depicted in Figure S1A). Proliferation assay PBMCs were isolated from healthy donors or oJIA patients as previously described and labeled in PBS with cell tracer violet (ctViolet, Life technologies, Carlsbad USA) in a final concentration of 2 μm for exactly 7 min at 37 °C and immediately washed in ice cold 100% FCS once, followed by washing in ice cold 10% FCS. Cells were subsequently incubated for 4 days in culture medium and stimulated with coated aCD3 1,5ug/ml (OKT3 eBioscience™, San Diego USA) in the presence of NAM versus untreated control. Cells were measured by flow cytometry. FlowJo v10 was used for data analysis and calculating the division index. The division index represents the average number of cell divisions of the original cells including the undivided cells. Suppression assay Treg cells from PBMCs from healthy donors were sorted via Flow cytometry based on CD3+CD4+CD25highCD127low (Gating strategy depicted in Figure S2A) after a CD4+ T cell enrichment using the CD4+ T cell negative selection kit and automatic magnetic activated cell sorting (Miltenyi Biotech Bergisch Gladbach, Germany). This strategy consistently leads to a population comprising > 80% FOXP3⁺ cells (Figure S2B). Next, Treg cells were incubated o/n in the presence of IL-2 (50U/ml) to promote Treg survival in the absence of T cell receptor stimulation [35, 36] and pre-treated with different concentrations of NAM. The next day, cells were thoroughly washed and added in a ratio of 1:4 or 1:8 to a proliferation assay performed with Celltrace CFSE (CFSE proliferation kit, Thermofisher, Waltham USA) labelled PBMCs stimulated with coated aCD3 0,1ug/ml (OKT3 eBioscience™) without the addition of NAM. Treg cells and PBMCs were matched to the same donor. Cells were incubated for 4 days after which proliferation was assessed by flow cytometry. Suppressive capacity was calculated based on the relative proliferation of the CD4+ or CD8+ T cell fraction within cultured PBMCs in the presence of Tregs compared with PBMCs cultured alone, using the following formula: 100 − ((percentage proliferation in the presence of Tregs / percentage proliferation in the absence of Tregs) × 100; [37]. Study design and clinical trial For this open-labeled exploratory phase II trial, 6 patients from the age of 16 years and older, with the diagnosis of either oJIA or pJIA and under treatment of the pediatric rheumatology department of the WKZ/UMC Utrecht between 2019 and 2021 were included. The inclusion criteria were active diseases and a clinical indication for intra-articular corticosteroid injection. They received standard of care and were treated with additional NAM therapy (1.8 g/m2/day in 3 doses) for the duration of 3 days before their planned intra-articular corticosteroid injection (rounded to 200 mg tablets). On day 3 right after the last dosage of NAM and immediately prior to the intra-articular corticosteroid injection blood was drawn to determine the peak level at T=1 hour and T=2 hour together with synovial fluid at T=2 hour. This study was conducted according to the criteria of the declaration of Helsinki [38].Written informed consent was obtained from all participants, and the study was approved by the Utrecht Ethics committee Utrecht (METC 18–586/EudraCT number 2018-002245-11). An overview of the study protocol is depicted in supplementary Figure S3. Measurement of NAM concentrations Patient plasma and SF samples were obtained and frozen at < -80 °C within 1 h. Samples were measured in duplicates with liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a lower limit of quantification (LLOQ) of 5 mg/L. Statistical analysis Statistical analysis was performed using Graphpad Prism 10. The statistical tests used to test significance are specified in the figure legends. For experiments evaluating the effects of NAM, samples were paired between NAM-treated and control conditions and analyzed accordingly. p-values were calculated using a paired t-test or one-way ANOVA when indicated, ns: not significant, *: p < 0.05, **: p < 0.01, ***: p < 0.005, ****: p < 0.001. Results NAM increases the proportion of FOXP3-expressing cells within the CD4+ T cell compartment and suppresses the proliferation of effector T cells in vitro To investigate the effect of NAM on the FOXP3 expression in CD4+ T cells in vitro, PBMCs were freshly isolated from healthy donors and cultured with increasing concentrations of NAM for four days in the presence of TCR stimulation. Flow cytometric analysis showed a dose-dependent increase in the proportion of FOXP3-expressing CD4+ T cells following NAM treatment (Fig. 1A/S4A). Importantly, this finding was confirmed in synovial fluid mononuclear cells (SFMCs) isolated from JIA patients (Fig. 1B/C/S4B), suggesting that NAM treatment could also increase the FOXP3-expressing CD4+ T cell proportion in SF. To assess whether this effect would result in a decreased proliferation of CD4+ and CD8+ T cells, freshly isolated PBMC and SF from JIA patients were labeled with ctViolet and subsequently activated in the presence of NAM for four days. This resulted in a dose dependent reduction in proliferation of both CD4+ and CD8+ T cells in both peripheral blood and SF from JIA patients (Fig. 1D). Together these data indicate that NAM treatment in vitro promotes FOXP3 expression in CD4+ T cells and suppresses CD4+ and CD8+ T cell proliferation in both peripheral blood and SF. NAM increases the proportion of FOXP3 expressing CD4+ T cells and decreases proliferation of CD4+ and CD8+ T cells in vitro. A CD4+ T cells from PBMCs from healthy donors activated in the presence of NAM in a concentration of 1mM, 3mM and 9mM versus untreated condition (N=8). Gated on CD3+CD4+(gating strategy depicted in Fig S1). B CD4+T cells from SFMCs isolated from SF of five JIA patients activated in the presence of NAM in a concentration of 1mM, 3mM and 9mM versus untreated (N=5). Gated on CD3+CD4+. C Histogram of a representative example of B; untreated (Blue) vs NAM treated 9mM (green) CD4+ T cells. D PBMCs and SFMCs labelled with ctViolet and stimulated with coated aCD3 for 4 days in the presence of different concentrations of NAM (1mM-9mM) versus untreated control. Division index of CD4+ T cells, selected by gating on CD3+CD4+ and CD3+CD8+ T cells (N=4). E Histogram of a representative example of D; unstim (grey), untreated (blue) vs NAM treated 9mM (green). Statistical significance was measured by paired one-way ANOVA. Bars: SD depicted. *: p < 0.05, **: p < 0.01, ***: p < 0.005, ****: p < 0.001, ns: non-significant NAM increases FOXP3 expression in Treg cells and enhances Treg suppressive capacity in vitro Previously we demonstrated that NAM treatment decreased effector T cell activation [33]. Consequently, the observed reduction in CD4+ and CD8+ T cell proliferation in SF following NAM incubation could result from a direct inhibitory effect of NAM on CD4+ and CD8+ T cells. Alternatively, it could (partly) be explained by an indirect effect through enhanced suppression by FOXP3-expressing CD4+ T cells, either by an increase in Treg cell numbers or an increased suppressive capacity. We therefore assessed whether pre-treatment of sorted Treg cells, identified as CD3+CD4+CD25highCD127low (Figure S2) would also result in a suppression of effector T cell proliferation with the absence of NAM in the co-culture. Here, sorted Treg cells showed an increase in FOXP3 expression when treated with NAM 9mM o/n without any form of stimulation (Fig. 2A). The suppressive capacity of the NAM treated Treg cells was subsequently assessed in a proliferation assay where they showed to have enhanced suppressive capacity (Fig. 2B/S5). These findings indicate that NAM not only induces FOXP3 expression in the CD4+ T population but also promotes FOXP3 expression in isolated Treg cells, resulting in increased suppressive function. NAM increases FOXP3 expression in Treg cells and improves Treg suppressive function A Sorted Treg cells (sorting strategy depicted in Fig S2) incubated o/n in the presence of NAM in a concentration of 3mM and 9mM versus untreated. N = 6 (untreated and 9mM NAM) and N = 4 (3mM NAM). B paired data plot of suppression assay (gating strategy depicted in Fig S5A) performed with sorted Treg cells pre-treated o/n with NAM in a concentration of 3mM and 9mM versus untreated (N = 6). Statistical significance was determined by paired one-way ANOVA. )). *: p < 0.05, **: p < 0.01, ns: non-significant A three-day oral suppletion regimen of NAM in JIA patients results in comparable concentrations of NAM in blood plasma and SF The observed effects of NAM on Treg cell suppressive function highlights its potential as a therapeutic candidate for autoimmune diseases in which Treg cells play an important role, such as JIA. To evaluate the pharmacokinetic properties of NAM and its capacity to penetrate the inflamed tissue, we aimed to assess NAM concentrations in both peripheral blood and SF after oral administration of NAM. Background levels of NAM in PB and SF are extremely low with concentrations that vary between 0.02 and 0.49 umol/L (Fig. 3). In our exploratory clinical trial, oral NAM was administered for three consecutive days to 6 JIA patients after which NAM concentrations were determined in both peripheral blood and SF (Fig. 3). NAM concentrations ranged from 0.06 to 0.18 mmol/L, which is approximately a thousand-fold higher than untreated controls. Mean concentrations measured 2 h after the final dose were 0.11 mmol/L in peripheral blood and 0.12mmol/L in SF, indicating adequate joint penetration. Furthermore, although there was a very short duration of treatment, the NAM treatment was well tolerated, and no serious side effects were reported. These findings demonstrate that NAM can reach concentrations up to 0.18 mmol/L within the joint compartment of JIA patients and support its further investigation as a safe and potentially effective immunomodulatory therapy targeting Treg cell function. NAM penetration in SF and blood A Baseline characteristics of patients included in the trial B Baseline characteristics of control oJIA patients for baseline levels C NAM concentrations measured in peripheral blood and SF at 1 h (T = 1) and 2 h (T = 2) following the final NAM administration in JIA patients treated with nicotinamide (N = 6). Control paired SF and PB from untreated oJIA patients (N = 5) Discussion In this study, we demonstrate that NAM treatment leads to an increased percentage of FOXP3-expressing CD4+ T cells in both PB from healthy controls and SF from JIA patients. In addition, Treg suppressive capacity of isolated Tregs form PB of healthy controls was enhanced after NAM treatment. Furthermore, data from our exploratory pilot clinical trial demonstrates that following oral administration, NAM reaches comparable concentrations in SF and PB, supporting its ability to penetrate the inflamed joint environment. This finding supports NAM’s potential to modulate immune response not only systemically but also locally at the site of inflammation. Previously, we have shown that NAM directly inhibits CD4+ T cell activation, as reflected by reduced proliferation and decreased production of pro-inflammatory cytokines [33]. Together with our current data, this suggests that NAM has the capacity to affect both the regulatory and the effector sides of the immune response in children. These findings are particularly relevant in the context of JIA, where disease pathogenesis is characterized by an imbalance between effector and regulatory T cell subsets, leading to inflammation and tissue damage. Although the precise molecular mechanisms underlying NAM’s immunomodulatory effects remain incompletely understood, NAM has been shown to influence cellular metabolism, activation and differentiation across a range of immune mediated and inflammatory diseases [28–32, 39]. NAM is not only the metabolic precursor of NAD+ but also a well-documented inhibitor of Poly (ADP-ribose) polymerase 1 (PARP-1) and the NAD+ dependent deacetylase Sirtuin 1 (SIRT-1), both of which are key regulators of different cellular functions, including immune responses [40–46]. SIRT1 mediates the deacetylation of the transcription factor FOXP3, leading to its destabilization and proteasomal degradation. Consequently, inhibition of SIRT1 by NAM enhances FOXP3 acetylation and stability, thereby promoting T-reg cell differentiation and function [9]. To translate our current findings using NAM as a potential (adjuvant) treatment modality in JIA, an important consideration is its safety profile. Numerous clinical trials, involving large groups of participants, demonstrated that NAM in high dosages is safe for long-term use in both adult and pediatric populations [28, 29, 31, 47–49]. A limitation of this study is that the in vitro NAM concentrations used to elicit functional effects on CD4+ T cells and Treg cells in our experiments are substantially higher than those achieved in vivo after short-term treatment. Therefore, the observed effects in vitro cannot directly be extrapolated to in vivo conditions. It should be noted that the in vitro assays make use of broad and strong T cell receptor stimuli, whereas in vivo activation of T cells in the joint is specific and probably less abundant. Moreover, in vitro experiments are designed to elicit measurable responses within a short time frame and do not capture the complex interactions among diverse immune cell populations present in vivo. Furthermore, although control NAM levels were determined in children under the age of 16, due to ethical considerations, the clinical trial was conducted exclusively in patients with JIA aged 16 years and older. Therefore, it remains uncertain whether this cohort is fully representative of the broader pediatric JIA population. Consequently, while NAM demonstrates modulatory effects on T cells under these controlled conditions, direct extrapolation of these findings to the clinical setting should be approached with caution. Finally, it is important to discuss our findings in the context of the intended use of NAM suppletion in clinical practice. We envision NAM as add-on treatment in patients that have been successfully treated with conventional DMARD/biologicals, and who are eligible to try to taper and/or stop their DMARD/biologicals. In this context, NAM maintenance treatment may reduce the chance of disease flare by its immunomodulatory effects on both regulatory T cell subsets as well as effector cells. It’s clear that further studies are warranted to determine optimal dosing regimens that achieve biologically relevant concentrations in target tissues, including the possibility of NAM accumulation in SF after long term treatment, while maintaining safety. Given that JIA is a systemic autoimmune disease and in patients with JIA there is an upregulation of Treg in both SF and PB [26] it is likely that NAM’s immunomodulatory effects are not limited to SF. Thus, NAM may exert effects both systemically and/or locally within the inflamed synovial tissue. Another important limitation of this study is that the specific subset of CD4⁺ T cells exhibiting FOXP3 upregulation was not further characterized. The phenotypic and functional definition of Tregs remains a subject of ongoing debate, particularly with respect to their heterogeneity and suppressive capacity in JIA [23, 26, 50–57]. Although crucial for Treg suppressive function, FOXP3 expression by itself is therefore insufficient to determine a Treg or the capacity for a T cell to be immune suppressive. Given that circulating Tregs, depending on their phenotypic definition, approximately comprises less than 5% of PB CD4+ T cells in patients with JIA, it is unlikely that the observed increase in FOXP3+ cells within the CD4+T cell population predominantly represents Tregs [58]. Notably, FOXP3 expression is not restricted to Treg cells and may also be transiently induced in activated conventional CD4⁺ T cells [26, 55, 57, 59], which is likely the case in the present experimental setting. However, FOXP3 can also exert immunomodulatory effects in other T cell subtypes, including partial suppression of effector functions such as cytokine production and proliferation [60–64]. Therefore, in vivo effects of NAM on CD4+ T cells activation in both blood and SF need to be assessed. This should comprise a more comprehensive characterization of its effect on effector T cell and Treg function and phenotype, including the evaluation of markers such as cytotoxic T lymphocyte associated protein 4 (CTLA4), inducible T cell co-stimulator (ICOS), glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) and Helios next to FOXP3. In conclusion, our current findings warrant further investigation of NAM as a potential candidate for (adjuvant) therapy in autoimmune diseases such as JIA. By enhancing percentages of FOXP3-expressing CD4+ T cells and Treg suppressive function, while at the same time limiting effector T cell activation, NAM could potentially help restore immune tolerance and reduce flares after cessation of treatment with biologicals. Clinical trials assessing the immunomodulatory and therapeutic effects of NAM in JIA are needed to determine its efficacy and tolerability over extended treatment periods. Additionally, mechanistic studies exploring how Treg stability and function is affected after NAM treatment In JIA patients are needed to gain further insight. Supplementary Information Supplementary Material 1: Figure S1: gating strategy figure 1A and B (A), patient demographics of Figure 1B (B). Figure S2: sorting strategy of Tregs Figure 2 (A), FOXP3 expression within CD25highCD125low gated population (B). Figure S3: schematic overview of study protocol. Figure S4: representative examples of Figure 1A (A) and B (B). Figure S5: gating strategy (A), representative example (B). Table S1: List of antibodies used for flow cytometry experiments. Acknowledgements The authors thank the patients for participation in the clinical trial and the Utrecht core flow facility. Abbreviations Juvenile Idiopathic Arthritis regulatory T Forkhead BoxP3 Polyendocrinpathy, Enteropathy, X-linked Synovial Fluid Disease-Modifying Antirheumatic Drugs Nicotinamide Nicotinamide Adenine Dinucleotide Peripheral Blood Mononuclear Cells Synovial Fluid Mononuclear Cells Poly (ADP-ribose) polymerase 1 Sirtuin 1 Cytotoxic T Lymphocyte Associated protein 4 Inducible T cell Co-Stimulator Glucocorticoid-Induced Tumor necrosis factor receptor-Related protein Authors’ contributions Conceptualization, L.N., J.v.L., and S.J.V.; investigation, L.N., R.C.S. AL; writing—original draft preparation, L.N.; writing—review and editing, L.N, J.v.L., S.J.V.; supervision, J.v.L. and S.J.V.; project administration, L.N.; funding acquisition, J.v.L. and S.J.V. All authors have read and agreed to the published version of the manuscript. Funding This research was funded by the Dutch arthritis society (ReumaNederland), grant number LLP10, together with the UMC Utrecht& Wilhelmina Kinderziekenhuis Foundation. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Informed consent was obtained from all subjects involved in the study. The study procedures were approved by the Institutional Review Board of the University Medical Center Utrecht (Clinical Trial UMCU; METC 18–586 and Pharmachild registry METC no: 11-499c) The study was conducted in accordance with the Declaration of Helsinki. Consent for publication Not applicable, no identifiable information about the study participants is included in this paper. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Sebastiaan J Vastert and Jorg van Loosdregt PhD contributed equally to this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.